LITS
Lite·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LITS
Lite Strategy, Inc.
A company established in2018,originally focused on business consulting,has now transformed into a digital asset vault management company specializing in Litecoin reserves
9920 Pacific Heights Blvd., Suite 150, San Diego, CA 92121
--
Lite Strategy, Inc., is a clinical-stage pharmaceutical company dedicated to the development of new and differentiated cancer therapies. The company builds its pipeline by acquiring promising cancer drugs and creates value in projects through clinical development, strategic partnerships, and outsourcing licensing or commercialization, as the case may be. Their pipeline of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3Kδ inhibitor, a preclinical drug candidate.
Company Financials
EPS
LITS has released its 2025 Q4 earnings. EPS was reported at -0.4, versus the expected 0, missing expectations. The chart below visualizes how LITS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
